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Abstract
Potentially novel regulators of early human germlineBackground: 
development have been identified recently, including SOX15 and SOX17,
both of which show specific expression in human primordial germ cells.
SOX17 is now known to be a critical specifier of human germ cell identity.
There have been suggestions, as yet without evidence, that SOX15 might
also play a prominent role. The early human germline is inaccessible for
direct study, but an   model of human primordial germ cell-like cellin vitro
(hPGCLC) specification from human embryonic stem cells (hESCs) has
been developed. This enables mechanistic study of human germ cell
specification using genetic tools to manipulate the levels of SOX15 and
SOX17 proteins to explore their roles in hPGCLC specification.
SOX15 and SOX17 proteins were depleted during hPGCLCMethods: 
specification from hESCs using the auxin-inducible degron system,
combined with a fluorescent reporter for tracking protein levels.
Additionally, SOX15 protein was overexpressed using the ProteoTuner
system. Protein-level expression changes were confirmed by
immunofluorescence. The impact on hPGCLC specification efficiency was
determined by flow cytometry at various time points. qPCR experiments
were performed to determine some transcriptional effects of SOX15
perturbations.
We observed specific SOX15 expression in hPGCLCs by usingResults: 
immunofluorescence and flow cytometry analysis. Depletion of SOX15 had
no significant effect on hPGCLC specification efficiency on day 4 after
induction, but there was a significant and progressive decrease in
hPGCLCs on days 6 and 8. By contrast, depletion of SOX17 completely
abrogated hPGCLC specification. Furthermore, SOX15 overexpression
resulted in a significant increase in hPGCLC fraction on day 8. qPCR
analysis revealed a possible role for the germ cell and pluripotency
regulator PRDM14 in compensating for changes to SOX15 protein levels.
SOX17 is essential for hPGCLC specification, yet SOX15 isConclusions: 
dispensable. However, SOX15 may have a role in maintaining germ cell
identity.
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Introduction
Despite decades of research, the genetic regulation of 
mammalian germline development is still only partially 
understood, especially in the case of the human germline. 
Primordial germ cells (PGCs) are the founder cells of sperm and 
eggs, which are specified shortly after blastocyst-implantation 
and preceding gastrulation1. This stage of human development is 
inaccessible for direct study, although experiments in mice and 
other animals have identified some important regulatory 
factors2. Later stages of human PGC (hPGC) development, when 
they migrate to the developing gonad, have been studied using 
fetal tissue samples, but these samples are highly limited in their 
availability and cannot be genetically manipulated.
More recently, a model system has been developed in which 
pluripotent stem cells can be induced to differentiate into 
PGC-like cells (PGCLCs) in response to signaling by BMP and 
other cytokines3. Mouse PGCLCs can develop further in vitro 
when co-cultured with E12.5 ovarian somatic cells in the 
presence of a defined set of cytokines and hormones; a 
few of them can even develop into functional oocytes4. 
Although a similar system has been recently reported to pro-
duce small numbers of human oogonia using coculture 
with mouse fetal ovarian somatic tissue5, the precise factors 
required for hPGC maturation and epigenetic resetting remain 
unknown, and the current human PGCLC (hPGCLC) model 
system only allows study of cells in the pre-migratory state3,6.
Solving this problem requires understanding the differences 
in gene regulation between hPGCs and mPGCs. In mice, PGC 
fate is specified by a core network of three transcription factors: 
BLIMP1, PRDM14, and AP2γ2,7. These genes are also impor-
tant in hPGCs8,9, but their activities depend on SOX17, which 
is the crucial specifier of hPGC fate6. Indeed, pigs, which 
are not closely related to primates, rely on SOX17 for germ-
line specification10, suggesting that the SOX17-driven mode of 
PGC specification is likely to represent a pathway conserved 
among non-rodent mammals11.
SOX17 is not the only regulatory gene that differs between 
mPGCs and hPGCs. SOX15, another member of the SOX 
family, is strongly expressed in hPGCs, but is absent in mPGCs12. 
Indeed, a recent single-cell transcriptomics study on human fetal 
PGCs found that expression of SOX15 mRNA was stronger and 
relatively more homogenous than SOX17 among hPGCs before 
10 weeks’ gestation, and the authors claimed that SOX15 is 
probably functionally more important for hPGC development 
in vivo13.
In both mice and humans, SOX15 is highly expressed in naïve 
ESCs, placenta, and muscle satellite cells14. Loss of SOX15 
function in mice produces a relatively mild phenotype, except 
for impaired muscle regeneration after injury15. Notably, fertility 
is normal, ruling out a crucial role for SOX15 in mPGCs. 
The SOX factors are classified into groups A–H based on 
phylogenetic analysis of their high-mobility group (HMG) 
DNA-binding domains16. SOX15 is the only group G SOX 
factor in mammals, although its HMG domain is similar to 
that of group B SOX factors such as SOX216. Interestingly, 
SOX2 is expressed in mPGCs but not hPGCs17,18, whereas 
SOX15 shows the opposite pattern12,13. In mESCs, SOX2 
knockout, which causes differentiation and loss of pluripo-
tency, can be rescued by overexpression of SOX1519. In contrast, 
SOX17 overexpression causes differentiation to endodermal 
lineages, even when SOX2 is present as normal20. Furthermore, 
in both mice and humans the structures of SOX15 and SOX17 
are relatively dissimilar16. Although SOX15 and SOX17 have 
similar expression patterns in hPGCs13, their transcriptional 
roles may differ.
In this work, we investigated the role of SOX15 during the 
specification of hPGCLCs in vitro and compared it with 
SOX17. To do this, we manipulated levels of these proteins 
using the auxin-inducible degron (AID)21 and ProteoTuner22 
systems, which allow for tight protein-level control with good 
temporal resolution. The AID system involves fusing a short 
degron peptide to the protein of interest, and also expressing 
a TIR1 E3 ubiquitin ligase21,23. In the presence of auxin (indole-
3-acetic acid (IAA)), TIR1 will ubiquitylate the degron, 
leading to destruction of the target protein by the proteasome. 
This happens rapidly, causing complete depletion within one 
hour. The presence of a Venus fluorescent reporter tag is 
compatible with AID, and this combination has previously been 
used successfully in hPGCLCs8. In accordance with the known 
role for SOX17 in the human germline, we found that its depletion 
prevented hPGCLC specification. In contrast, we found that 
SOX15 is dispensable for establishing hPGCLC identity, but may 
play a role in maintaining it. Furthermore, we identified some 
transcriptional effects of SOX15 depletion and overexpression. 
Altogether, we show the utility of genetic tools, which rapidly 
alter protein levels, for providing insights into genetic regulation 
of the early human germline.
Methods
Cell culture
hESCs (WIS2 (46XY) cell line24 obtained from the Weizmann 
Institute, with NANOS3-T2A-tdTomato (N3tdT) reporter 
subsequently introduced10) were cultured in 4i medium6,24, 
containing cytokines TGFβ, bFGF, and LIF, as well as four 
small-molecule inhibitors for kinases MAPK, MEK, JNK, 
and GSK3. This medium, which was prepared as previously 
described6, allows hESCs to be continually maintained in a germ-
line competent state. The hESCs were grown on a layer of irra-
diated CF1 mouse embryonic fibroblasts (MEFs) (Applied Stem 
Cell). The MEFs were plated at approximately 15,000 cells/cm2 
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on gelatin-coated plates in DMEM supplemented with 10% 
FBS, 100 U/mL penicillin, and 0.1 mg/mL streptomycin. 
Medium was changed daily for hESCs. Passages were 
performed using 0.25% trypsin/EDTA with ROCK inhibitor 
(10 µM Y-27632, Tocris Bioscience) added to the medium. 
All cells were maintained in an incubator at 37°C and 5% 
CO2. Cell lines used in the experiments tested negative for 
mycoplasma.
Generation of mutant cell lines
For CRISPR/Cas9 experiments, gRNAs were chosen using 
the online tool at crispr.mit.edu (accessed October 2018; this 
resource is no longer functional but contains links to multiple 
free-to-use alternatives). Oligos were annealed and cloned into 
eSpCas9(1.1) vector25 digested with BbsI. Homology arms 
(approximately 1 kb each) were amplified by PCR from genomic 
DNA of the target cell line, with a point mutation introduced 
to remove the stop codon and CRISPR PAM. The homology- 
directed repair donor plasmids were assembled using 
InFusion cloning (Clontech). For ProteoTuner overexpression, 
SOX15 cDNA was cloned into the PB-EF1-myc-DD-IRES-Puro 
backbone using InFusion. This plasmid was stably integrated 
into N3tdT hESCs using the PiggyBac system8. Full plasmid 
sequences with annotation are listed in the Extended data26. All 
oligos used for cloning and sequencing are listed in Extended 
Table 127. Plasmids were delivered using Lipofectamine Stem 
reagent (Invitrogen) according to manufacturer’s instructions. 
After 48 hours, selection was begun with puromycin 
(0.5 µg/mL), hygromycin (50 µg/mL), and/or FIAU (200 nM) 
as appropriate, and continued until colonies were picked. 
Genotyping gels for AID knock-ins are shown in Extended 
Figure 128. After the AID tag was introduced, cells were 
subsequently transfected with TIR1 using the PiggyBac system8, 
and the selectable marker was excised using transient expression 
of Dre recombinase29.
hPGCLC induction
For hPGCLC induction, hESCs cultured in 4i medium were 
dissociated with 0.25% trypsin/EDTA. The cells were suspended 
in MEF medium to quench the trypsin, and the suspension was 
filtered through a 50-µm strainer. The cells were pelleted by 
centrifugation (300g, 4 minutes) and resuspended in hPGCLC 
base medium10 (Advanced RPMI 1640 (Thermo Fisher), 
supplemented with 2 mM L-glutamine, 0.1 mM non-essential 
amino acids, 1% B27 supplement (Thermo Fisher), 100 U/mL 
penicillin, 0.1 mg/mL streptomycin, 10 µM Y-27632, 0.25% w/v 
poly(vinyl alcohol), and 10 ng/mL hLIF). Cells were counted 
(Invitrogen Countess) and the suspension was diluted to 
40,000 live cells/mL in hPGCLC medium (hPGCLC base plus 
500 ng/mL BMP2, 100 ng/mL SCF, and 50 ng/mL EGF). Next, 
100 µL of suspension, containing 4000 cells, was added to 
each well of a 96-well ultra-low-attachment plate (Corning 
CoStar). Cells were pelleted (300g, 2 minutes) and the plate 
was incubated (37°C, 5% CO2). For experiments beyond day 
6 of culture, a 50% medium change was performed on day 
6. Details of each separate biological replicate (144 in total), 
including timepoints, are listed in Extended Table 3 (for 
SOX15 and SOX17 AID experiments), Extended Table 4 
(for SOX15-AID time course experiments), or Extended Table 5 
(for SOX15-DD experiments)27.
AID experiments
For AID, IAA sodium salt was prepared as a stock solution 
in water (500 mM) and added to the cell culture medium at a 
final concentration of 100 µM. In SOX15-AID time-course 
experiments where the IAA was added after induction, 
10 µL of 1.1 mM IAA in hPGCLC base medium were 
added. In these experiments, 10 µL of hPGCLC base medium 
containing no IAA were also added to control wells. For 
ProteoTuner experiments, Shield1 was used at a concentration of 
0.5 µM.
Flow cytometry
Embryoid bodies (EBs) were collected, washed with PBS, and 
dissociated by digesting with 0.25% trypsin/EDTA (5 µL per 
EB) for 10 minutes at 37°C with gentle shaking (600 rpm). 
For day 6 and older EBs, dissociation was completed by pass-
ing the suspension multiple times through a 27-gauge needle. 
Trypsin was quenched with two volumes of ice-cold sorting 
medium (3% FBS in PBS) and the cells were pelleted (300g, 
2 minutes). Next, the cells were resuspended in sorting 
medium (5 µL per EB) containing a 1:60 dilution of AF647 
conjugated mouse anti-human tissue non-specific alkaline 
phosphatase IgG (BD Biosciences, catalog No. 561500, 
RRID AB_10717125) and incubated at 4°C in the dark for 
30 minutes. The antibody solution was diluted with two 
volumes of sorting medium, and the cells were pelleted 
(300g, 2 minutes) and resuspended in 500 µL sorting medium 
plus DAPI (0.1 µg/mL). The suspension was filtered with a 
50 µm strainer and analyzed on a flow cytometer (BD LSR-
Fortessa or Sony 800Z). Cells in FACS experiments were 
sorted directly into 50 µL RNA extraction buffer (Arcturus 
PicoPure, Thermo Fisher) which was frozen at –80°C for 
subsequent use. RNA was extracted following the manufacturer’s 
instructions.
Quantitative reverse-transcription PCR (qPCR)
cDNA synthesis was performed using the Quantitect Reverse 
Transcription kit (Qiagen) following the manufacturer’s 
instructions. qPCR reactions were performed at 10 µL scale in 
384-well plate format using the SYBR Green JumpStart Taq 
ReadyMix (Sigma-Aldrich) on a QuantStudio 6 Flex instru-
ment (Applied Biosystems). The following protocol was used for 
thermocycling: initial denaturation 95°C, 10 minutes, followed 
by 40 cycles of 95°C denaturation for 15 seconds and 60°C 
annealing/extension for 1 minute. Primers are listed in 
Extended Table 127. Two technical replicates were performed 
for each biological replicate. Details, including mean Ct values, 
for all biological replicates (80 in total) are listed in Extended 
Table 927. Analysis was performed using the QuantStudio 
software. The ∆∆Ct method was used for quantification, with 
GAPDH as a reference transcript.
Immunofluorescence
For immunofluorescence in hESCs, cells were grown on 
Ibidi 8-well plates. Cells were washed with PBS, fixed with 
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4% paraformaldehyde in PBS at room temperature (RT) for 
10 minutes, and washed again with PBST (0.1% Triton 
X-100 (Sigma) in PBS) three times. Cells were permeabilized 
with 0.25% Triton X-100 (Sigma) in PBS for 10 minutes, 
then blocked with blocking buffer (5% normal donkey serum 
(Stratech) and 1% bovine serum albumin (Sigma) in PBST) 
at RT for 30 minutes. Cells were incubated with primary 
antibodies (Extended Table 2)27 in blocking buffer overnight 
at 4°C, then washed three times with PBST. Cells were 
incubated with secondary antibodies (Extended Table 2)27 in 
blocking buffer at RT for one hour, then incubated with 
0.5 ng/mL DAPI in PBS for 10 minutes. Cells were washed 
three times with PBS and stored at 4°C in the dark until imaging 
(up to one week).
For immunofluorescence in EBs, the EBs were fixed with 
4% paraformaldehyde in PBS at 4°C for 1 hour, then washed 
with PBS and transferred to 10% sucrose in PBS. When EBs 
had sunk, the process was repeated with 20% sucrose. EBs 
were then embedded in OCT compound (CellPath) and cryo-
sectioned using a Leica CM3050S cryostat to 8-µm thickness 
on SuperFrost Plus slides (VWR). Slides were air-dried for 
1 hour at RT, then stained for immunofluorescence as described 
above, except that the permeabilization was performed with 
0.1% Triton X-100 and the DAPI was added during second-
ary antibody incubation. Slides were mounted in Prolong Gold 
Antifade medium with DAPI (Molecular Probes). Imaging 
for all samples was performed with an SP5 confocal laser 
scanning microscope (Leica) and images were analyzed using 
Fiji software (version 2.0.0)30.
Statistical analysis
For flow cytometry data, the hPGCLC fraction (listed in 
Extended Tables 3–5)27 was calculated using FlowJo software 
(version 10.0.7). For each induced cell line, the fold change 
was calculated as the ratio of hPGCLC fraction in treated (with 
IAA or Shield1, depending on experiment) and untreated 
samples. This step was performed in order to control for 
the batch-to-batch variability between different hPGCLC 
inductions. The fold change values were then compared for 
experimental cell lines (overexpression or depletion) and control 
cell lines (either SOX15-AID-Venus with no TIR1, or parental 
N3tdT). This was done in order to control for any nonspecific 
effects of Shield1 or IAA (a known aryl hydrocarbon 
receptor agonist31). The Wilcoxon rank-sum test was used for 
comparisons, since by the Kolmogorov-Smirnov test the data 
were not normally distributed.
For qPCR data, differentially expressed genes were determined 
by Z-test on the ∆∆Ct data. This test was chosen because 
the data did not significantly deviate from normality by the 
Kolmogorov-Smirnov test. The Holm-Bonferroni method was 
used to correct for multiple comparisons. All data points were 
included in analysis, except those from reactions that did not 
amplify due to low target concentration.
Statistical analysis was performed in R (version 3.2.3) using 
the RStudio environment (version 1.2.1335). p < 0.05 was used 
as a significance threshold for all tests. Sample sizes were not 
determined in advance. Investigators were not blinded during 
experiments and analysis.
Results
Depletion of SOX15 during hPGCLC specification using AID
To determine the effects of SOX15 depletion on hPGCLC 
specification, a homozygous knock-in cell line with a C-terminal 
AID-Venus tag on SOX15 was generated by a strategy similar 
to one previously used for PRDM148. The parental line had a 
NANOS3-T2A-tdTomato (N3tdT) reporter, which is expressed 
specifically in hPGCLCs10. Immunofluorescence experiments 
confirmed SOX15 expression at the protein level in hPGCLCs 
within the EBs (Figure 1); this is consistent with the previous 
RNA-seq data6,13. The expression of SOX15 was first observed 
at a faint level on day 1 after induction, and more strongly on 
day 2. Expression continued in OCT4/BLIMP1-positive hPG-
CLCs until the end of the time-course experiment (day 6) 
(Figure 1). The neighboring somatic lineages (soma) were 
almost completely SOX15-negative: there were a small number 
of SOX15-positive, OCT4/BLIMP1 negative cells on days 
2–4, but by day 5, SOX15 expression was completely confined 
to hPGCLCs.
To deplete SOX15, SOX15-AID/TIR1 cells were treated with 
IAA at the start of hPGCLC induction. Immunofluorescence 
performed on day 4 after induction showed depletion of 
SOX15-AID-Venus to background levels (Figure 2A). SOX15- 
AID-Venus expression in untreated cells was similar to that 
observed in the previous experiment. SOX17 was used as a 
marker for hPGCLCs, and SOX17-positive cells were present 
in both samples. To quantify any effects of SOX15 depletion on 
hPGCLC specification efficiency, flow cytometry was per-
formed on cells from dissociated EBs either treated or untreated 
with IAA. Identification of hPGCLCs was performed using a 
combination of the NANOS3-T2A-tdTomato reporter and 
antibody staining against the alkaline phosphatase surface 
marker. The results indicated that on day 4 after induction, 
there was no significant effect of SOX15 depletion on induction 
efficiency (Figure 2B). However, at later time points (days 6 
and 8), depletion of SOX15 resulted in a significant reduc-
tion of the fraction of hPGCLCs (Figure 2C). Notably, the 
effect was much milder that that reported for SOX17 deple-
tion, which resulted in complete loss of hPGCLCs6,8. The pro-
gressive decrease in hPGCLC fraction upon prolonged SOX15 
depletion suggests that SOX15 may have a role in hPGCLC 
maintenance.
The rapid kinetics of SOX15 depletion by the AID system 
enabled an investigation of the effects of SOX15 depletion start-
ing at various time points after induction. IAA was added on 
days 0 through 5 and the hPGCLC fraction present on day 6 
(Figure 2D) was measured by flow cytometry, which also 
confirmed SOX15 depletion even after only one day of IAA 
treatment (Figure 2E). As expected, the effect on hPGCLC 
fraction diminished when IAA was added at later time points, 
but there was a significant decrease on day 6 when SOX15 was 
depleted starting on day 4 or earlier. There were no statistically 
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Figure 1. Timecourse immunofluorescence of SOX15-AID-Venus embryoid bodies (EBs). EBs were stained with DAPI (grey), anti-Venus 
(green), anti-OCT4 (red), and anti-BLIMP1 (cyan). Scale bar is 50 µm. SOX15 expression is observed faintly on day 1 and robustly on day 2, 
persisting in OCT4/BLIMP1 positive cells for the remainder of the experiment.
significant differences in the magnitude of these decreases 
with SOX15 depleted from day 4 or earlier (Wilcoxon test, 
p > 0.05). Interestingly, depletion from day 0 did not produce 
a significant effect on hPGCLC fraction measured on day 4 
(Figure 2C), but depletion from day 4 significantly reduced 
hPGCLC fraction measured on day 6 (Wilcoxon test, p = 0.02). 
Since the hPGCLC transcriptional network is already largely 
established by day 26, this suggests that SOX15 depletion 
might interfere with hPGCLC survival or proliferation even 
when specification proceeds normally.
SOX15 overexpression experiments using ProteoTuner
To further elucidate the functional role of SOX15 in 
hPGCLC specification, we performed overexpression of 
SOX15 using the ProteoTuner system22. This consists of a 
destabilizing domain (DD) fused to the protein target, which 
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Figure 2. SOX15 depletion by auxin-inducible degron  (AID).  (A) SOX15-AID-Venus expression is observed in SOX17-positive human 
primordial germ cell-like cells (hPGCLCs). A few SOX17-positive Venus-negative somatic cells are also present; these are likely definitive 
endoderm6. SOX15-AID-Venus, but not SOX17, is depleted to background levels with indole-3-acetic acid (IAA) treatment. Staining for 
TIR1-myc indicates ubiquitous expression. Scale bar is 50 µm. (B) Representative flow cytometry analysis of SOX15-AID-Venus protein 
expression and hPGCLC markers. hPGCLCs were identified based on NANOS3-T2A-tdTomato expression and AP surface staining. IAA 
treatment results in a near-total reduction of Venus-positive cells on day 4. However, this only causes a slight decrease in the fraction of 
AP+/NANOS3+ hPGCLCs. (C) Prolonged SOX15 depletion decreases AP+/NANOS3+ hPGCLC fraction. Embryoid bodies were treated with 
IAA from the start of induction, with hPGCLC fraction measured by flow cytometry on day 4, 6, or 8. Fractions were normalized with respect 
to untreated samples of the same clones. Statistical comparisons were performed between SOX15-AID/TIR1 clones and control clones 
without TIR1, which did not deplete SOX15. (D) Effects of SOX15 depletion at various times during hPGCLC specification. IAA treatment was 
begun on the day indicated, with AP+/NANOS3+ hPGCLC fraction measured on day 6. Fractions were normalized with respect to untreated 
samples of the same clones. Comparisons shown are relative to control cell lines (without TIR1). Significance values are by Wilcoxon test 
(*p < 0.05, **p < 0.01, ***p < 0.001). Each point represents a biological replicate. (E) Venus fluorescence intensity in NANOS3+/AP+ PGCLCs 
was measured by flow cytometry. In the absence of IAA, SOX15-AID-Venus fluorescence was similar to its levels in the parental cell line 
without TIR1. This shows that TIR1 does not cause leaky depletion of SOX15. When IAA was added on day 5, by day 6 the Venus fluorescence 
was depleted to background levels, similar to the N3tdT cell line which lacks Venus completely.
normally results in protein degradation. Upon addition of a 
stabilizing ligand (Shield1), protein levels increase quickly. 
The ProteoTuner system has rapid kinetics22 similar to those of 
the AID system21.
hESC cell lines were generated expressing SOX15 with 
N-terminal myc tag and C-terminal DD, under the control of 
the constitutively active EF1α promoter. After selection, clones 
were tested for Shield1-dependent expression by immunofluo-
rescence after 1 hour of treatment (Figure 3A). Two suitable 
clones were identified with homogeneous expression of myc-
SOX15-DD protein, observed only in the presence of Shield1. 
Subsequently, these cells were induced to form hPGCLCs in 
the presence or absence of Shield1. On day 4 post-induction, 
Shield1 treatment resulted in myc-SOX15-DD expression in 
both hPGCLCs and soma as judged by immunofluorescence 
(Figure 3B).
To quantify the effect of SOX15 overexpression on hPGCLC 
induction efficiency, the EBs were dissociated and analyzed 
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Figure  3.  SOX15  overexpression  by  ProteoTuner.  (A) Human embryonic stem cells (hESCs) express myc-SOX15-DD after one hour 
of treatment with Shield1. hESC colonies were grown on a layer of MEFs and stained for IF using anti-myc antibody. myc-SOX15-DD 
successfully localizes to the nucleus. Scale bar is 50 µm. (B) In a Shield1-dependent manner, EBs overexpress myc-SOX15-DD in both 
SOX17-positive human primordial germ cell-like cells (hPGCLCs) as well as somatic cells. Scale bar is 50 µm. (C) SOX15 overexpression 
increases hPGCLC fraction. EBs were treated with Shield1 starting at the beginning of induction, and AP+/NANOS3+ hPGCLC fraction 
was measured by flow cytometry on day 4, 6, or 8. Fractions were normalized with respect to untreated samples of the same clones. 
Significance values are by Wilcoxon test (*p < 0.05, **p < 0.01, ***p < 0.001). Each point represents a biological replicate.
by flow cytometry. Notably, there was a higher fraction of 
hPGCLCs in EBs overexpressing SOX15 (Figure 3C). This dif-
ference was statistically significant on day 8 (Wilcoxon test, 
p = 0.02), which was not the case on days 4 and 6. Taken 
together with the delayed effects of SOX15 depletion observed 
in the AID experiments, this further supports a potential role 
for SOX15 in hPGCLC maintenance, possibly by promoting 
survival or proliferation.
Transcriptional effects of SOX15 perturbation
To test for transcriptional effects of SOX15 depletion and 
overexpression, we assembled a set of candidate genes including 
both known regulators of germline identity, and previously 
reported SOX15 targets in other cell types, including 
human embryonal carcinoma cells32, muscle satellite cells33, 
esophageal34 and pancreatic35 adenocarcinomas, and mouse 
ESCs36. We investigated transcriptional changes for these 
genes in hPGCLCs after SOX15 protein was either depleted or 
overexpressed. We used the day 6 timepoint for experiments 
based on our hPGCLC analysis described above. Depletion 
of SOX15 during hPGCLC specification caused significant 
upregulation of PRDM14, AKAP1, BEND4, VENTX, SOX15, 
and NANOG as shown by qPCR analysis (Figure 4A) (Z test 
with Holm-Bonferroni correction, p < 0.05); PRDM14, VENTX, 
SOX15, and NANOG are known to be associated with germ cell 
identity1,2, perhaps suggesting a compensatory effect. Notably, 
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Figure  4. Transcriptional  effects  of  SOX15  perturbation.  Expression of candidate genes was measured by qPCR to determine the 
effects of (A) SOX15 depletion from human primordial germ cell-like cells (hPGCLCs) (B) SOX15 overexpression in hPGCLCs (C) SOX15 
overexpression in soma. The cell populations were separated by flow cytometry prior to RNA extraction. Each point represents a 
biological replicate. Green bars represent significantly upregulated genes, and red bars significantly downregulated ones (Z-test with 
Holm-Bonferroni correction, p < 0.05). (D) Relative expression levels of SOX17 and POU5F1 in hPGCLCs and soma with and without SOX15 
overexpression.
the upregulation of SOX15 implies negative feedback, while 
AKAP1, VENTX, and BEND4 are known targets of PRDM14 in 
hPGCLCs8, so their upregulation may be indirect.
In contrast, hPGCLCs with SOX15-DD overexpression showed 
transcriptional changes that were generally the opposite of 
the SOX15-AID hPGCLCs (Figure 4B). PRDM14, AKAP1, 
VENTX, and ELF3 were significantly downregulated (Z test with 
Holm-Bonferroni correction, p < 0.05). The first three of these 
genes were upregulated in SOX15-AID. Interestingly, SOX15-
DD overexpression also had distinct effects in the somatic cells of 
the EBs. FOXK1, a transcription factor known to promote aerobic 
glycolysis37, was significantly downregulated. Additionally, SOX17 
and POU5F1 (encoding OCT4) were significantly upregulated, 
showing an approximately twofold increase (Figure 4C), 
although their initial expression in untreated somatic cells 
was low (Figure 4D). These genes are highly expressed in 
hPGCLCs, and SOX17 in particular is crucial for establishing their 
identity6.
AID depletion of SOX17 using inducible TIR1
SOX17 is known to play a crucial role in PGC specification and 
is expressed from an early stage in the process. Previous AID 
experiments on SOX17 have shown that its depletion abrogates 
hPGCLC specification8. However, the cell lines used in those 
experiments had poor hPGCLC induction efficiency (~5%) even 
in the absence of IAA. We hypothesized that this was due to 
depletion of SOX17 even in absence of IAA. Similar leaky 
depletion has been previously reported for a few targets38. To 
overcome this leakiness, we created cell lines expressing TIR1 
under the control of the ProteoTuner system (TIR1-DD). In 
this inducible AID system, protein target depletion should 
occur upon administration of two ligands: Shield1 to stabilize 
auxin hormone receptor (TIR1) and IAA to initiate target 
degradation. We performed a preliminary test of kinetics 
in PRDM14-AID-Venus hESCs8. By immunofluorescence, a 
TIR1-DD hESC line depleted PRDM14 after 1 hour of 
treatment with IAA and Shield1 (Figure 5A), with minor 
heterogeneity.
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Figure 5. AID depletion of PRDM14 and SOX17 using  inducible TIR1.  (A) PRDM14-AID-Venus/TIR1-DD human embryonic stem cells 
(hESCs) grown on a layer of mouse embryonic fibroblasts were treated with indole-3-acetic acid (IAA) and/or Shield1. After one hour of 
treatment, cells were fixed and stained for IF using anti-GFP. Scale bar is 50 µm. (B) SOX17 depletion abrogates hPGCLC induction. SOX17-
AID-Venus hESCs, expressing TIR1-DD either from AAVS1 or from random PiggyBac integration, were induced to form hPGCLCs with and 
without Shield1 and IAA. AP+/NANOS3+hPGCLC fraction was measured by flow cytometry after four days. Fractions were normalized with 
respect to untreated samples of the same clones. Results from cells without TIR1 are plotted for comparison. Significance values are by 
Wilcoxon test (*p < 0.05, **p < 0.01, ***p < 0.001). Each point represents a biological replicate. (C) SOX17 depletion by AID with TIR1-DD. 
SOX17-AID-Venus cells with PB-TIR1-DD were induced to form human primordial germ cell-like cells (hPGCLCs) and treated with IAA and 
Shield1 from the start of the induction. After four days, EBs were fixed, sectioned, and stained using antibodies against GFP and SOX17. The 
untreated sample contains many SOX17 positive hPGCLCs, whereas only a few are visible in the treated sample. Scale bar is 50 µm.
We next applied the inducible TIR1-DD to SOX17-AID by 
generating a cell line with EF-TIR1-DD, flanked by insulator 
sequences to prevent silencing39, knocked in to the AAVS1 locus. 
This cell line successfully formed hPGCLCs with efficiency 
8–17% (Extended Table 3)27. Although this was not quite as 
efficient as wild-type SOX17 cell lines (typically 30–50%), 
it still was an improvement over constitutive TIR1 cell lines, 
which at best gave roughly 5% efficiency8, and often gave less. 
However, the AAVS1-TIR1DD cells showed only a moderate 
depletion of SOX17 with IAA and Shield1 treatment 
(Figure 5B). Apparently the two copies of TIR1-DD at the 
AAVS1 locus were insufficient, or possibly silenced despite 
the insulators40, so we used PiggyBac transposase to deliver 
additional copies.
After screening clones, we identified three that were compe-
tent for hPGCLC specification but also depleted SOX17 almost 
completely with IAA and Shield1. As expected, this resulted 
in drastically reduced specification efficiency (Figure 5B) The 
efficiency in the absence of IAA and Shield1 was similar to the 
AAVS1-TIR1DD cell line. Notably, the few remaining hPGCLCs 
were all SOX17-positive by flow cytometry and immunofluo-
rescence (Figure 5C). This indicates that the presence of these 
hPGCLCs was due to slightly heterogeneous depletion, rather 
Page 10 of 19
Wellcome Open Research 2019, 4:122 Last updated: 23 SEP 2019
than SOX17 being dispensable. These data further confirm the 
crucial role of SOX17 for hPGCLC fate.
Discussion
Based on previous single-cell RNA-seq data, SOX15 had 
been suggested to be a critical regulator of human germ cell 
identity13. In hPGCs between gestational weeks 4 and 10, SOX15 
is more homogeneously expressed than SOX1713. However, AID-
mediated depletion of SOX15 during hPGCLC specification 
did not result in significant reduction in specification effi-
ciency, as would be expected if it were essential at this early 
stage. Unlike the dramatic effect seen with SOX17 depletion 
(Figure 5B), SOX15 depletion only resulted in a moderate 
decrease in hPGCLC fraction, and this effect was only signifi-
cant at later timepoints (days 6 and 8) (Figure 2C). Furthermore, 
by immunofluorescence, robust expression of SOX15 is detected 
only after day 2 of hPGCLC induction (Figure 1). This is later 
than the expression of SOX17 and BLIMP1, which are the 
key regulators of human germline fate6, so cells are already 
committed to the germ lineage by this time. These results do not 
support a critical role for SOX15 in germline specification.
In contrast to SOX15, SOX17 is strictly required for hPGCLC 
specification. As expected based on previous experiments6,8, 
depletion of SOX17 by AID resulted in a dramatic decrease in 
hPGCLC fraction. While an inducible TIR1-DD was required 
to overcome leakiness, this system had similar kinetics to the 
conventional AID system (Figure 5A), and the use of inducible 
TIR1-DD should not change the interpretation of the results. 
In addition to validating previous results with SOX17-AID8, 
these experiments serve as a proof of concept for an inducible 
AID system, where TIR1 is under ProteoTuner control. Such 
configuration can be of great value for some targets that are 
destabilized by AID even in the absence of IAA, as was the case 
for SOX17, thus expanding the utility of the AID system.
Although not absolutely necessary for hPGCLC specification, 
SOX15 may, however, play a role in maintenance of germ cells. 
AID experiments showed that prolonged SOX15 depletion 
decreased the hPGCLC fraction in EBs, with the effect 
increasing over time (Figure 2C). Furthermore, overexpres-
sion of SOX15 increased the hPGCLC fraction, again with the 
effect increasing over time (Figure 3C). Limitations in current 
methods for culturing hPGCLCs make it difficult to obtain 
meaningful results beyond day 8 due to degeneration of the 
EBs, but it may well be the case that SOX15 is required for 
long-term maintenance of germ cell identity, similar to its role 
in myogenic progenitors15,33,41,42 in which it prevents prema-
ture differentiation. Alternatively, the effects on hPGCLC 
fraction could reflect a role in survival or proliferation of 
hPGCLCs.
We also observed transcriptional changes in response to SOX15 
perturbation. The expression of PRDM14 and some of its 
known target genes8 were anticorrelated with SOX15 protein 
levels in hPGCLCs (Figure 4). Furthermore, the effects on 
SOX15 RNA levels in the AID experiments indicate negative 
feedback, which is possibly analogous to the feedback 
previously reported for Sox2 in mESCs43. The magnitude of 
the effects were however relatively modest (1.4 – 2.0 average 
fold change for the transcripts affected) within a small subset 
of the transcriptome we tested. We cannot therefore exclude 
a possibility that other SOX15 targets might be functionally 
relevant to a greater or lesser extent.
The effects of SOX15 perturbation on hPGCLC maintenance 
and transcriptional activity are better understood in context of its 
role in other cell types. Although SOX15 has not been 
investigated nearly as much as other SOX factors, the existing 
research on SOX15 suggests a role related to preventing improper 
growth and differentiation. In myogenic progenitors, SOX15 
promotes satellite cell maintenance, and thus has an important 
role in muscle regeneration15,33,41,42. In embryonal carcinoma32, 
and esophageal34 and pancreatic35 adenocarcinomas, SOX15 
acts as a tumor suppressor and lack of SOX15 is associated with 
aberrant growth. The tumor suppressive action of SOX15 
may be mediated through its downregulation of Wnt pathway 
components35,44. Notably, Wnt signaling promotes germline 
competence in mouse, pig, and human pluripotent cells, but after 
germline specification, excess Wnt signaling is detrimental8,10,45. 
Since PRDM14 is also known to repress Wnt targets8, the 
anticorrelation of PRDM14 with respect to SOX15 perturbations 
may be a compensatory mechanism to maintain Wnt signaling 
within the range compatible with germline identity.
Overall, our research has identified that SOX15 is dispensable 
for establishing human germline identity, unlike SOX17, which 
is strictly required. Thus, our results do not support a role for 
SOX15 in the early stages of hPGC specification in vivo. 
However, we found that SOX15 promotes hPGCLC maintenance, 
and it may play a similar role in the human germline.
Data availability
Underlying data
Figshare: Supplementary Tables for “Testing the role of SOX15 
in human primordial germ cell fate”. https://doi.org/10.6084/
m9.figshare.903423227.
This project contains the following underlying data:
•      Extended Table 3 SOX15_SOX17_AID_raw (PGCLC frac-
tion counts by flow cytometry).
•      Extended Table 4 SOX15AID_timecourse_raw (PGCLC 
fraction counts by flow cytometry).
•      Extended Table 5 SOX15DD_raw (PGCLC fraction counts 
by flow cytometry).
•      Extended Table 6 qPCR_SOX15AID (∆∆Ct values for 
SOX15-AID).
•      Extended Table 7 qPCR_SOX15DD_PGCLC (∆∆Ct values 
for SOX15 PGCLCs).
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•      Extended Table 8 qPCR_SOX15DD_SOMA (∆∆Ct 
values for SOX15 somatic cells).
•      Extended Table 9 CT_raw (Raw Ct values).
Figshare: SOX15-Venus / OCT4 / BLIMP1 timecourse 
immunofluorescence raw images. https://doi.org/10.6084/
m9.figshare.910443546.
Figshare: myc-SOX15-DD / SOX17 immunofluorescence PGCLCs 
raw images. https://doi.org/10.6084/m9.figshare.910447147.
Figshare: myc-SOX15-DD immunofluorescence ESCs raw images. 
https://doi.org/10.6084/m9.figshare.910449548.
Figshare: SOX15-Venus / SOX17 / myc-TIR1 immunofluores-
cence SOX15-AID PGCLCs raw images. https://doi.org/10.6084/
m9.figshare.910450449.
Figshare: PRDM14-AID Venus / TIR1-DD ESCs immunofluores-
cence raw images. https://doi.org/10.6084/m9.figshare.910466650.
Figshare: Raw FCS files for “Testing the role of SOX15 in 
human primordial germ cell fate”. https://doi.org/10.6084/
m9.figshare.938561651.
Extended data
Figshare: Supplementary Tables for “Testing the role of SOX15 
in human primordial germ cell fate”. https://doi.org/10.6084/
m9.figshare.903423227.
This project contains the following extended data:
•      Extended Table 1 (oligonucleotides) (oligonucleotide 
primers used in this study).
•      Extended Table 2 (primary antibodies for immunofluo-
rescence).
Figshare: Extended Figure 1: Genotyping gels. https://doi.
org/10.6084/m9.figshare.924899628.
Figshare: Plasmids for “Testing the role of SOX15 in human 
primordial germ cell fate”. https://doi.org/10.6084/
m9.figshare.903419926.
Data are available under the terms of the Creative Commons 
Zero “No rights reserved” data waiver (CC0 1.0 Public domain 
dedication).
Acknowledgements
We thank Naoko Irie and Walfred Tang for some qPCR primers.
References
1. Kobayashi T, Surani MA: On the origin of the human germline. Development. 
2018; 145(16): pii: dev150433.  
PubMed Abstract | Publisher Full Text 
2. Magnúsdóttir E, Dietmann S, Murakami K, et al.: A tripartite transcription factor 
network regulates primordial germ cell specification in mice. Nat Cell Biol. 
2013; 15(8): 905–915.  
PubMed Abstract | Publisher Full Text | Free Full Text 
3. Irie N, Surani MA: Efficient Induction and Isolation of Human Primordial Germ 
Cell-Like Cells from Competent Human Pluripotent Stem Cells. Methods Mol 
Biol. (ed. Buszczak, M.) Springer New York, 2017; 1463: 217–226.  
PubMed Abstract | Publisher Full Text 
4. Hikabe O, Hamazaki N, Nagamatsu G, et al.: Reconstitution in vitro of the 
entire cycle of the mouse female germ line. Nature. 2016; 539(7628): 299–303. 
PubMed Abstract | Publisher Full Text 
5. Yamashiro C, Sasaki K, Yabuta Y, et al.: Generation of human oogonia from 
induced pluripotent stem cells in vitro. Science. 2018; 362(6412): 356–360. 
PubMed Abstract | Publisher Full Text
6. Irie N, Weinberger L, Tang WW, et al.: SOX17 is a critical specifier of human 
primordial germ cell fate. Cell. 2015; 160(1–2): 253–268.  
PubMed Abstract | Publisher Full Text | Free Full Text 
7. Nakaki F, Hayashi K, Ohta H, et al.: Induction of mouse germ-cell fate by 
transcription factors in vitro. Nature. 2013; 501(7466): 222–226.  
PubMed Abstract | Publisher Full Text
8. Sybirna A, Tang WWC, Dietmann S, et al.: A critical but divergent role of 
PRDM14 in human primordial germ cell fate revealed by inducible degrons. 
bioRxiv. 2019.  
Publisher Full Text 
9. Kojima Y, Sasaki K, Yokobayashi S, et al.: Evolutionarily Distinctive 
Transcriptional and Signaling Programs Drive Human Germ Cell Lineage 
Specification from Pluripotent Stem Cells. Cell Stem Cell. 2017; 21(4):  
517–532.e5.  
PubMed Abstract | Publisher Full Text 
10. Kobayashi T, Zhang H, Tang WWC, et al.: Principles of early human 
development and germ cell program from conserved model systems. Nature. 
2017; 546(7658): 416–420.  
PubMed Abstract | Publisher Full Text | Free Full Text 
11. Sybirna A, Wong FCK, Surani MA: Genetic basis for primordial germ cells 
specification in mouse and human: Conserved and divergent roles of PRDM 
and SOX transcription factors. Curr Top Dev Biol. Elsevier, 2019; 135: 35–89. 
PubMed Abstract | Publisher Full Text 
12. Sarraj MA, Wilmore HP, McClive PJ, et al.: Sox15 is up regulated in the 
embryonic mouse testis. Gene Expr Patterns. 2003; 3(4): 413–417.  
PubMed Abstract | Publisher Full Text 
13. Guo F, Yan L, Guo H, et al.: The Transcriptome and DNA Methylome 
Landscapes of Human Primordial Germ Cells. Cell. 2015; 161(6): 1437–1452. 
PubMed Abstract | Publisher Full Text 
14. Yamada K, Kanda H, Aihara T, et al.: Mammalian Sox15 gene: promoter analysis 
and implications for placental evolution. Zoolog Sci. 2008; 25(3): 313–320. 
PubMed Abstract | Publisher Full Text 
15. Lee H-J, Göring W, Ochs M, et al.: Sox15 is required for skeletal muscle 
regeneration. Mol Cell Biol. 2004; 24(19): 8428–8436.  
PubMed Abstract | Publisher Full Text | Free Full Text 
16. Kamachi Y, Kondoh H: Sox proteins: regulators of cell fate specification and 
differentiation. Development. 2013; 140(20): 4129–4144.  
PubMed Abstract | Publisher Full Text 
17. Campolo F, Gori M, Favaro R, et al.: Essential role of Sox2 for the establishment 
and maintenance of the germ cell line. Stem Cells. 2013; 31(7): 1408–1421. 
PubMed Abstract | Publisher Full Text 
18. Tang WWC, Dietmann S, Irie N, et al.: A Unique Gene Regulatory Network Resets 
the Human Germline Epigenome for Development. Cell. 2015; 161(6): 1453–1467. 
PubMed Abstract | Publisher Full Text | Free Full Text 
19. Niwa H, Nakamura A, Urata M, et al.: The evolutionally-conserved function of 
group B1 Sox family members confers the unique role of Sox2 in mouse ES 
cells. BMC Evol Biol. 2016; 16: 173.  
PubMed Abstract | Publisher Full Text | Free Full Text 
20. Niakan KK, Ji H, Maehr R, et al.: Sox17 promotes differentiation in mouse 
embryonic stem cells by directly regulating extraembryonic gene expression 
and indirectly antagonizing self-renewal. Genes Dev. 2010; 24(3): 312–326. 
PubMed Abstract | Publisher Full Text | Free Full Text 
21. Natsume T, Kiyomitsu T, Saga Y, et al.: Rapid Protein Depletion in Human Cells 
by Auxin-Inducible Degron Tagging with Short Homology Donors. Cell Rep. 
2016; 15(1): 210–218.  
PubMed Abstract | Publisher Full Text 
22. Maynard-Smith LA, Chen L, Banaszynski LA, et al.: A directed approach for 
Page 12 of 19
Wellcome Open Research 2019, 4:122 Last updated: 23 SEP 2019
engineering conditional protein stability using biologically silent small 
molecules. J Biol Chem. 2007; 282(34): 24866–24872.  
PubMed Abstract | Publisher Full Text | Free Full Text 
23. Nishimura K, Fukagawa T, Takisawa H, et al.: An auxin-based degron system for the 
rapid depletion of proteins in nonplant cells. Nat Methods. 2009; 6(12): 917–922.  
PubMed Abstract | Publisher Full Text 
24. Gafni O, Weinberger L, Mansour AA, et al.: Derivation of novel human ground 
state naive pluripotent stem cells. Nature. 2013; 504(7479): 282–286.  
PubMed Abstract | Publisher Full Text 
25. Slaymaker IM, Gao L, Zetsche B, et al.: Rationally engineered Cas9 nucleases 
with improved specificity. Science. 2016; 351(6268): 84–88.  
PubMed Abstract | Publisher Full Text | Free Full Text 
26. Pierson Smela M, Sybirna A, Wong FCK, et al.: Plasmids for “Testing the role of 
SOX15 in human primordial germ cell fate”. figshare. Dataset. 2019.
27. Pierson Smela M, Sybirna A, Wong FCK, et al.: Supplementary Tables for 
“Testing the role of SOX15 in human primordial germ cell fate”. figshare. 
Dataset. 2019. 
28. Pierson Smela M, Sybirna A, Wong FCK, et al.: Extended Figure 1: Genotyping 
gels. figshare. Figure. 2019. 
29. Anastassiadis K, Fu J, Patsch C, et al.: Dre recombinase, like Cre, is a highly 
efficient site-specific recombinase in E. coli, mammalian cells and mice. Dis 
Model Mech. 2009; 2(9–10): 508–515.  
PubMed Abstract | Publisher Full Text 
30. Schindelin J, Arganda-Carreras I, Frise E, et al.: Fiji: an open-source platform for 
biological-image analysis. Nat Methods. 2012; 9(7): 676–682.  
PubMed Abstract | Publisher Full Text | Free Full Text 
31. Heath-Pagliuso S, Rogers WJ, Tullis K, et al.: Activation of the Ah receptor by 
tryptophan and tryptophan metabolites. Biochemistry. 1998; 37(33): 11508–11515. 
PubMed Abstract | Publisher Full Text 
32. Yan H-T, Shinka T, Sato Y, et al.: Overexpression of SOX15 inhibits proliferation 
of NT2/D1 cells derived from a testicular embryonal cell carcinoma. Mol Cells. 
2007; 24(3): 323–328.  
PubMed Abstract 
33. Meeson AP, Shi X, Alexander MS, et al.: Sox15 and Fhl3 transcriptionally 
coactivate Foxk1 and regulate myogenic progenitor cells. EMBO J. 2007; 26(7): 
1902–1912.  
PubMed Abstract | Publisher Full Text | Free Full Text 
34. Sulahian R, Chen J, Arany Z, et al.: SOX15 governs transcription in human 
stratified epithelia and a subset of esophageal adenocarcinomas. Cell Mol 
Gastroenterol Hepatol. 2015; 1(6): 598–609.e6.  
PubMed Abstract | Publisher Full Text | Free Full Text 
35. Thu KL, Radulovich N, Becker-Santos DD, et al.: SOX15 is a candidate tumor 
suppressor in pancreatic cancer with a potential role in Wnt/β-catenin 
signaling. Oncogene. 2014; 33(3): 279–288.  
PubMed Abstract | Publisher Full Text 
36. Maruyama M, Ichisaka T, Nakagawa M, et al.: Differential roles for Sox15 and 
Sox2 in transcriptional control in mouse embryonic stem cells. J Biol Chem. 
2005; 280(26): 24371–24379.  
PubMed Abstract | Publisher Full Text 
37. Sukonina V, Ma H, Zhang W, et al.: FOXK1 and FOXK2 regulate aerobic 
glycolysis. Nature. 2019; 566(7743): 279–283.  
PubMed Abstract | Publisher Full Text 
38. Yesbolatova A, Natsume T, Hayashi KI, et al.: Generation of conditional auxin-
inducible degron (AID) cells and tight control of degron-fused proteins using 
the degradation inhibitor auxinole. Methods. 2019; 164–165: 73–80.  
PubMed Abstract | Publisher Full Text 
39. Mossine VV, Waters JK, Hannink M, et al.: piggyBac transposon plus insulators 
overcome epigenetic silencing to provide for stable signaling pathway 
reporter cell lines. PLoS One. 2013; 8(12): e85494.  
PubMed Abstract | Publisher Full Text | Free Full Text 
40. Ordovás L, Boon R, Pistoni M, et al.: Efficient Recombinase-Mediated Cassette 
Exchange in hPSCs to Study the Hepatocyte Lineage Reveals AAVS1 Locus-
Mediated Transgene Inhibition. Stem Cell Reports. 2015; 5(5): 918–931.  
PubMed Abstract | Publisher Full Text | Free Full Text 
41. Béranger F, Méjean C, Moniot B, et al.: Muscle differentiation is antagonized by 
SOX15, a new member of the SOX protein family. J Biol Chem. 2000; 275(21): 
16103–16109.  
PubMed Abstract | Publisher Full Text 
42. Savage J, Conley AJ, Blais A, et al.: SOX15 and SOX7 differentially regulate the 
myogenic program in P19 cells. Stem Cells. 2009; 27(6): 1231–1243.  
PubMed Abstract | Publisher Full Text 
43. Masui S, Nakatake Y, Toyooka Y, et al.: Pluripotency governed by Sox2 via 
regulation of Oct3/4 expression in mouse embryonic stem cells. Nat Cell Biol. 
2007; 9(6): 625–635.  
PubMed Abstract | Publisher Full Text 
44. Moradi A, Ghasemi F, Anvari K, et al.: The cross-regulation between SOX15 and 
Wnt signaling pathway. J Cell Physiol. 2017; 232(12): 3221–3225.  
PubMed Abstract | Publisher Full Text 
45. Hackett JA, Huang Y, Günesdogan U, et al.: Tracing the transitions from pluripotency 
to germ cell fate with CRISPR screening. Nat Commun. 2018; 9(1): 4292.  
PubMed Abstract | Publisher Full Text | Free Full Text 
46. Pierson Smela M, Sybirna A, Wong FCK, et al.: SOX15-Venus / OCT4 / BLIMP1 
timecourse immunofluorescence raw images. figshare. Dataset. 2019. 
47. Pierson Smela M, Sybirna A, Wong FCK, et al.: myc-SOX15-DD / SOX17 
immunofluorescence PGCLCs raw images. figshare. Dataset. 2019. 
48. Pierson Smela M, Sybirna A, Wong FCK, et al.: myc-SOX15-DD 
immunofluorescence ESCs raw images. figshare. Dataset. 2019. 
49. Pierson Smela M, Sybirna A, Wong FCK, et al.: SOX15-Venus / SOX17 / myc-TIR1 
immunofluorescence SOX15-AID PGCLCs raw images. figshare. Dataset. 2019. 
50. Pierson Smela M, Sybirna A, Wong FCK, et al.: PRDM14-Venus / TIR1-DD 
immunofluorescence PRDM14-AID ESCs raw images. figshare. Dataset. 2019. 
51. Pierson Smela M, Sybirna A, Wong FCK, et al.: Raw FCS files for “Testing the 
role of SOX15 in human primordial germ cell fate. figshare. Dataset. 2019. 
Page 13 of 19
Wellcome Open Research 2019, 4:122 Last updated: 23 SEP 2019
 Open Peer Review
  Current Peer Review Status:
Version 2
 23 September 2019Reviewer Report
https://doi.org/10.21956/wellcomeopenres.16931.r36536
© 2019 Payer B. This is an open access peer review report distributed under the terms of the Creative Commons
, which permits unrestricted use, distribution, and reproduction in any medium, provided the originalAttribution License
work is properly cited.
   Bernhard Payer
 Centre for Genomic Regulation (CRG), Barcelona Institute of Science and Technology (BIST),
Barcelona, Spain
 Universitat Pompeu Fabra, Barcelona, Spain
The authors have addressed all points to my satisfaction.
 No competing interests were disclosed.Competing Interests:
Reviewer Expertise: Germ Cell Development, Stem Cell Reprogramming, Epigenetics, X-Chromosome
Reactivation.
I confirm that I have read this submission and believe that I have an appropriate level of
expertise to confirm that it is of an acceptable scientific standard.
Version 1
 13 September 2019Reviewer Report
https://doi.org/10.21956/wellcomeopenres.16803.r36242
© 2019 Robertson E. This is an open access peer review report distributed under the terms of the Creative Commons
, which permits unrestricted use, distribution, and reproduction in any medium, provided the originalAttribution License
work is properly cited.
 Elizabeth Robertson
Sir William Dunn School of Pathology, Oxford University, Oxford, UK
This paper by Pieron Smela and colleagues addresses the potential role for the Sox family transcription
1
2
Page 14 of 19
Wellcome Open Research 2019, 4:122 Last updated: 23 SEP 2019
 This paper by Pieron Smela and colleagues addresses the potential role for the Sox family transcription
factor Sox15 in specification of human primordial germ cells (PGCs).
 
Interestingly both Sox 15 and the closely related family member Sox17 are highly expressed in human
PGCs. Sox17 has previously been shown by this group to have an essential role on PGC specification,
that seems to be unique for human PGCs, using   protocols that induce the formation of so-termedin vitro
human PGCLC from cultured hESCs using soluble cytokines. The current work tests the hypothesis that
Sox15 may similarly be required for pluripotent cells to adopt this specialized cell fate. 
 
Using a very well designed experimental strategy to efficiently remove Sox15 during   specificationin vitro
of hPGCLC via an auxin-inducible degron system, the authors find that Sox15 depletion has no noticeable
impact on the efficiency with which PGCLC can be induced at day 4. However, with time they show that
the numbers progressively decrease. By contrast over-expression of Sox15 using a ProteoTuner
approach had the reciprocal effect, namely an increase in the number of PGCLCs formed in the cultures.
This observation was validated by q-PCR analysis of a set of selected genes. 
 
As a control for the experimental system, and as a further proof of concept of the
inducible/over-expression protocols presented, they nicely demonstrate that, as predicted, depletion of
Sox17 completely abrogates PGCLC induction.
 
Overall, the experiments summarized in the 5 Figures are very clearly displayed and the data and analysis
are very clear. The conclusion that Sox15 is not essential for human PGC specification will be of interest
to researchers in the field and the experimental protocols should be applicable for experiments designed
to further tease apart the molecular circuitry governing the formation of human PGCLC  . In myin vitro
opinion the paper should be accepted as is without any revisions.
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I confirm that I have read this submission and believe that I have an appropriate level of
expertise to confirm that it is of an acceptable scientific standard.
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© 2019 Payer B. This is an open access peer review report distributed under the terms of the Creative Commons
, which permits unrestricted use, distribution, and reproduction in any medium, provided the originalAttribution License
work is properly cited.
   Bernhard Payer
 Centre for Genomic Regulation (CRG), Barcelona Institute of Science and Technology (BIST),
Barcelona, Spain
 Universitat Pompeu Fabra, Barcelona, Spain
In this paper, the authors investigated the role of SOX15, a transcription factor which is highly expressed
in human primordial germ cells   similar to its paralog SOX17, which is a known critical factor forin vivo
human primordial germ cell-like cell (hPGCLC) differentiation from human embryonic stem cells (hESCs) 
. They thereby applied novel approaches like protein degradation by auxin-inducible degron (AID)in vitro
technology and protein overexpression by the ProteoTuner system. Surprisingly, SOX15 seemed to be
more important for maintenance of hPGCLCs instead of their specification. By testing the expression of
genes in SOX15-depleted or overexpressing cells, they identified   and   asPRDM14, SOX17 POU5F1
potential differentially regulated genes. As these are factors with known roles in pluripotency and germ
cell fate, these findings are potentially interesting and warrant further investigation.
The study introduces new resources by generating novel cell lines allowing tuning the protein expression
of the human germ cell factors SOX15 and SOX17. Thereby they will become useful tools for the
community to address the functions of SOX15 and SOX17 in the human germ cell lineage.
 
Specific comments
Page 3, paragraph 2, last sentence: “However, as opposed to mouse PGCs (mPGCs), the precise
conditions required for hPGC maturation and epigenetic resetting remain unknown, and the current
human PGCLC (hPGCLC) model system only allows study of cells in the pre-migratory state . " 
It is not entirely true that in the human system only a pre-migratory state has been achieved. A
recent study should be mentioned here (Yamashiro  ., (2018) ), in which human PGCLCs,et al
when co-cultured with mouse gonadal somatic cells, could advance to hPGCLC-derived oogonia
displaying partial epigenetic reprogramming.
 
Page 3, paragraph 3: “In mice, PGC fate is specified by a core network of three transcription
factors: BLIMP1, PRDM14, and AP2γ .”
Here the paper by Nakaki  ., (2013)  should also be cited.et al
 
Figures 2C, D, 3C, 5B, 18: The Y-axis label indicating PGCLC induction efficiency fold change
should be labeled better. In the figure legend, it needs to be stated, which antibody/reporter
stainings were measured to define the PGCLC fold change in FACS. Additionally, it is not clear,
why the control samples are not consistently set to 1 in these plots, but rather deviate from 1. The
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7.  
why the control samples are not consistently set to 1 in these plots, but rather deviate from 1. The
plots should be corrected, as by definition, the control should be set to 1 if the fold change in
treated samples is to be compared to the control. 
 
Figure 2D: It seems that there is a much stronger effect on hPGCLC numbers on day 6, if SOX15 is
depleted from day 0 onwards, when compared to depletion beginning at later time points, where
the effect seems to not increase with longer time of SOX15 depletion (depletion from days 1-4
seem to have equal effect). This suggests there might be also a potential role for SOX15 during
hPGCLC specification or right thereafter. The authors should consider this possibility. 
 
Figure 4D and page 8 paragraph 2: “Endogenous SOX15 expression was also downregulated on
average, although this effect was not statistically significant (p = 0.08 after Holm- Bonferroni
”. As the effect is extremely mild and not statistically significant, this sentence should becorrection)
omitted.
 
Figure 4: The genes, which were significantly up- or downregulated after SOX15-depletion or
overexpression changed mostly less than two-fold. Therefore these data need to be interpreted
with caution, as the changes are only very mild. Unbiased genome-wide expression analysis by
RNA-Seq could potentially identify more directly affected SOX15 targets and would provide more
insight than focusing only on select candidates. The authors should tone down the interpretation of
these expression data. 
 
Figure 5B+C. The figure legend is swapped between B+C. Please correct the mistake.
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, Wellcome Trust/CRUK Gurdon Institute, University of Cambridge,Merrick Pierson Smela
Cambridge, UK
We (the authors) have updated the article with a new version to address these comments:
1) Page 3, paragraph 2, last sentence: “However, as opposed to mouse PGCs (mPGCs), the
precise conditions required for hPGC maturation and epigenetic resetting remain unknown, and the
current human PGCLC (hPGCLC) model system only allows study of cells in the pre-migratory
state . " 
It is not entirely true that in the human system only a pre-migratory state has been achieved. A
recent study should be mentioned here (Yamashiro et al., (2018)), in which human PGCLCs, when
co-cultured with mouse gonadal somatic cells, could advance to hPGCLC-derived oogonia
displaying partial epigenetic reprogramming.
We have included this reference, and clarified that the use of mouse gonadal somatic cells leaves
unclear which precise factors are responsible for the maturation observed.
2) Page 3, paragraph 3: “In mice, PGC fate is specified by a core network of three transcription
factors: BLIMP1, PRDM14, and AP2γ .”
Here the paper by Nakaki et al., (2013) should also be cited.
We have included this reference.
3) Figures 2C, D, 3C, 5B, 18: The Y-axis label indicating PGCLC induction efficiency fold change
should be labeled better. In the figure legend, it needs to be stated, which antibody/reporter
stainings were measured to define the PGCLC fold change in FACS. Additionally, it is not clear,
why the control samples are not consistently set to 1 in these plots, but rather deviate from 1. The
plots should be corrected, as by definition, the control should be set to 1 if the fold change in
treated samples is to be compared to the control. 
We have updated the Y-axis labels and figure legends to include more information.
The controls were not set to 1 since the comparisons for statistical tests were between the
AID/TIR1 cell line fold change and the control cell line fold change, not between the AID/TIR1 cell
line fold change and 1. This was explained in the Methods section under “Statistical Analysis.”
Ideally the control cell line fold change would be equal to 1, since in the absence of experimental
variability and/or nonspecific effects the hPGCLC fraction would be the same with and without IAA.
In our experiments the control cell line fold change did vary somewhat, but was not significantly
different from 1 (one-sample Wilcoxon signed rank test, p > .05).
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 different from 1 (one-sample Wilcoxon signed rank test, p > .05).
4) Figure 2D: It seems that there is a much stronger effect on hPGCLC numbers on day 6, if
SOX15 is depleted from day 0 onwards, when compared to depletion beginning at later time
points, where the effect seems to not increase with longer time of SOX15 depletion (depletion from
days 1-4 seem to have equal effect). This suggests there might be also a potential role for SOX15
during hPGCLC specification or right thereafter. The authors should consider this possibility. 
Although the decrease when SOX15 was depleted from day 0 seemed stronger, this was not
significantly different from the decrease when SOX15 was depleted from days 1 – 4 (by Wilcoxon
test, p = 0.11, 0.30, 0.30, 0.11). We have added a sentence to the paper which describes this.
Although this lack of significance does not by itself rule out a potential role for SOX15 during
hPGCLC specification or right thereafter, in context of the data in Figure 2C we do not believe such
a potential role is likely to be crucial. In any case, we do not believe this merits further discussion in
the paper, especially given the next suggestion to remove a mention of a different statistically
insignificant effect.
5) Figure 4D and page 8 paragraph 2: “Endogenous SOX15 expression was also downregulated
on average, although this effect was not statistically significant (p = 0.08 after Holm- Bonferroni
correction)”. As the effect is extremely mild and not statistically significant, this sentence should be
omitted.
We have removed this sentence.
6) Figure 4: The genes, which were significantly up- or downregulated after SOX15-depletion or
overexpression changed mostly less than two-fold. Therefore these data need to be interpreted
with caution, as the changes are only very mild. Unbiased genome-wide expression analysis by
RNA-Seq could potentially identify more directly affected SOX15 targets and would provide more
insight than focusing only on select candidates. The authors should tone down the interpretation of
these expression data. 
We have added two sentences in the Discussion section mentioning these caveats. We agree that
RNA-seq experiments would have provided more insight had we done them.
7) Figure 5B+C. The figure legend is swapped between B+C. Please correct the mistake.
We have corrected this. 
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